The same in other media
Pfizer submits data to FDA on COVID-19 vaccine in kids ages 5 to 11
Reading now: 445
NEW YORK - Pfizer-BioNTech has submitted data to the U.S. Food and Drug Administration from the late-stage trial of its COVID-19 vaccine in children ages 5 to 11, saying the companies expect to formally submit a request for emergency approval in "the coming weeks."The Phase 2/3 trial data, collected from more than 2,2600 participants, will be reviewed by the FDA.
A formal submission to request emergency use authorization of the companies’ COVID-19 vaccine is expected to follow in the coming weeks, company officials said.The Pfizer COVID-19 vaccine is currently available in the U.S.
for those 12 and older, leaving many younger children still vulnerable amid the rapid spread of the delta variant of the coronavirus.
Read more on fox29.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
COVID-19
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|
